Avimex’s Covid Patria Vaccine: Effective Trials Show Promise Against Omicron and Its Variants This article explores the clinical trials of the Avimex laboratory’s Covid Patria vaccine (AVX/COVID-12), highlighting its effectiveness against the Omicron variant and potential versatility against other strains. General Director Bernardo Lozano Dubernard discusses the vaccine’s current status and its capacity for production. Furthermore, it touches on the international scope and future applications, emphasizing the innovation within Mexico’s scientific community.
Avimex’s COVID-19 Patria Vaccine: An Insight into Clinical Trials and Its Impact Introduction The Avimex laboratory, led by General Director Bernardo Lozano Dubernard, has recently announced the successful… The post <p><strong>Avimex’s Covid Patria Vaccine: Effective Trials Show Promise Against Omicron and Its Variants</strong></p> <p>This article explores the clinical trials of the Avimex laboratory’s Covid Patria … Read more